(Press-News.org) New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest. The research is by Dr Felix Kork and Professor Claudia Spies, Charité - University Medicine Berlin, Germany and colleagues.
Hospital mortality is subject to day-night, weekly and seasonal variability. This has been shown for various populations, settings, and in different regions of the world. However, a cyclic influence on hospital mortality has not been shown in patients after surgery. In this study, the researchers investigated the daily, weekly, and seasonal variability of hospital mortality in patients after surgery.
A retrospective analysis was carried out patients who underwent surgery between 2006 and 2011 at the two University Hospital Campuses of Charité Tertiary Care University Center, Berlin. Data was then modelled to work out cyclical patterns.
In this first analysis of the data, a total of 218,758 patients were included. Hospital mortality showed variability over the course of the day, during different weekdays, and different months. Surgery conducted in the afternoon was associated with 21% increased risk of death compared with surgery conducted at other times of day. Surgery at the weekend was associated with a 22% increased risk of death compared with surgery on weekdays. February was the highest risk month for surgery, with surgery in February associated with a 16% increased risk of death compared with surgery in all other months. Further work on the data will be carried out in the coming months, including looking at the possible reasons behind the variations.
The authors say: "Several factors may have influenced this outcome. For example, it may be that standard of care differs throughout the day and between weekdays and weekends. Although we controlled for risk factors including emergency surgery in our study, it may very well be that the patients treated in the afternoon and on the weekends were more severely ill. We need more data to draw conclusions regarding seasonal variation in postoperative outcome."
They add: "Despite having an accredited quality management system in place in our hospitals, as well as having the European Society of Anaesthesiology's Helsinki Declaration of Patient Safety in Anaesthesiology implemented, this study shows that we should seek to further improve patient safety."
INFORMATION: END
Risk of death highest following surgery in afternoons, at weekends, and in February
2014-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Poor coverage of specific gene sets in exome sequencing gives cause for concern
2014-06-01
With services based on exome sequencing becoming affordable to patients at a reasonable price, the question of the quality of the results provided has become increasingly important. The exome is the DNA sequence of genes that are translated into protein. These protein-coding regions contain most of the currently-known disease-causing genetic mutations. The American College of Medical Genetics and Genomics (ACMG) has recommended the reporting to patients of clinically actionable incidental genetic findings in the course of clinical exome testing. Specifically, mutations ...
Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
2014-05-31
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013. The drug also has shown dramatic responses in ...
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
2014-05-31
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, ...
ASCO: One step closer to a breath test for lung cancer
2014-05-31
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
"This could totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer," ...
ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
2014-05-31
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid ...
Patients with metastatic colon cancer respond to new combination therapy
2014-05-31
CHICAGO — In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's 2014 Annual Meeting in Chicago, examines a specific mutation in the BRAF gene, which is present in 5 to 10 percent of colorectal cancer patients.
Previous research identified this mutation ...
Immune therapy for advanced bladder cancer yields promising results
2014-05-31
New Haven, Conn. — A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.
The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 ...
Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL
2014-05-31
COLUMBUS, Ohio – In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. Ibrutinib (Imbruvica) is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation.
CLL, the most common form of leukemia, causes a gradual increase ...
Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting
2014-05-31
(New York – UNDER EMBARGO May 31, 2014) Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2014 American Society of Clinical Oncology (ASCO) meeting May 30-June 3, 2014 in Chicago, including data on new treatment approaches for thyroid, head and neck, and recurrent ovarian cancers; and new biomarkers for bile duct cancers.
Highlights of Mount Sinai research at ASCO:
Phase II Trial on the Combination of Bevacizumab and Irinotecan in Recurrent Ovarian Cancer (Under Embargo Until SATURDAY, MAY 31, 8:00 – 11:45 AM)
In a study ...
Researchers take a major step towards better diagnosis and treatment of osteoporosis
2014-05-31
A new target that may be critical for the treatment of osteoporosis, a disease which affects about 25% of post-menopausal women, has been discovered by a group of researchers in The Netherlands and in Germany. Professor Brunhilde Wirth, Head of the Institute of Human Genetics, University of Cologne, Germany, will tell the annual conference of the European Society of Human Genetics tomorrow (Sunday) that new studies in zebrafish and mice have shown that injection of human plastin 3 (PLS3) or related proteins in zebrafish where PLS3 action has been suppressed can replace ...